Eloralintide vs Pramlintide
A selective, long-acting amylin agonist that reaches GLP-1-class weight loss without touching the GLP-1 receptor. The first amylin analog — native amylin with its self-aggregation edited out. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
Eloralintide | Pramlintide | |
|---|---|---|
| Also known as | — | Symlin |
| Type | Analog | Analog |
| Evidence | Investigational | Established |
| Family | Incretins & metabolic | Incretins & metabolic |
| Class | Selective long-acting amylin analog (acylated 37 aa peptide) | Amylin analog (synthetic 37 aa peptide) |
| Receptor / target | Amylin receptors (calcitonin receptor + RAMP), AMY1-selective | Amylin receptors (calcitonin receptor + RAMP) |
| Molecular weight | ~4,526 Da | ~3,949.4 Da |
| Half-life | ||
| Based on | Amylin | Amylin |
Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between Eloralintide and Pramlintide?
- Eloralintide is an engineered analog based on Amylin; Pramlintide is an engineered analog based on Amylin. Eloralintide signals at Amylin receptors (calcitonin receptor + RAMP), AMY1-selective; Pramlintide signals at Amylin receptors (calcitonin receptor + RAMP).
- How do the half-lives of Eloralintide and Pramlintide compare?
- The reported circulating half-life of Eloralintide is ~13–15 days (310–366 h); Pramlintide is ~48 min. These are reference values for the native or representative form — educational only, not dosing advice.
Prefer the other order? Pramlintide vs Eloralintide. Or open the interactive comparison tool to add more molecules.